medigraphic.com
ISSN 0016-3813 (Print)

2010, Number 2

<< Back Next >>

Gac Med Mex 2010; 146 (2)

Melanoma cutáneo

Fuente-García A, Ocampo-Candiani J

Language: Spanish
References: 55
Page: 126-135
PDF size: 131.56 Kb.


ABSTRACT

Cutaneous melanoma is the most malignant skin tumor with great potential to develop metastases. For 50 years, its incidence has greatly increased worldwide, including Mexico. Although some risk factors are known, early diagnosis and treatment are still the only strategies that have shown to improve prognosis. Management of cutaneous melanoma is still a challenge. In this article we present a review and update of cutaneous melanoma, its epidemiology, etiology, risk factors, classification, diagnosis criteria, relevance of the sentinel node, management, treatment, and prevention.


REFERENCES

  1. Gutiérrez-Vidrio RM, Cortés-Lozano M. Confrontando al melanoma en el siglo XXI. Med Cutan Iber Lat Am 2007;35:3-13.

  2. Goldstein B, Goldstein A. Diagnosis and management of malignant melanoma. Am Fam Phys 2001;63:1359-1368.

  3. Arenas R. Atlas dermatología, diagnóstico y tratamiento. Tercera edición. México: McGraw-Hill Interamericana; 2009.

  4. Wolf K, Jonson RA, Surmond D. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. Fifth edition. USA: McGraw-Hill; 2005.

  5. Tsao H, Atkins M, Sober A. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.

  6. Martínez-Said H, Cuéllar-Hubbe M, Barrón-Velásquez E, Padilla RA, Herrera-Gómez A, López-Graniel CM. Epidemiology of cutaneous melanoma in Mexico (1982-2002). Eur J Surg Oncol 2004;30:163.

  7. Jacobo R, Pineda B, León G. Melanoma maligno cutáneo. Perfil epidemiológico en México. Gaceta Mex Oncol 2003;2:17-22.

  8. Habif T. Habif: Clinical Dermatology. Fourth edition. Philadelphia: Mosby Elsevier; 2004.

  9. Antoniou C, Kosmadaki M, Stratigos A, Katsambas A. Sunscreens: what’s important to know. J Eur Acad Dermatol Venereol 2008;22:1110-1118.

  10. Schaffer J, Rigel D, Kopf A, Bolognia J. Cutaneous melanoma. Past, present, and future. J Am Acad Dermatol 2004;51:S65-S69.

  11. Miller A, Mihm MJ. Melanoma. N Engl J Med 2006;355:51-65.

  12. Puig S, Malvehy J, Badenas C, Ruiz A, Jiménez D, Cuéllar F, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-3051.

  13. Heymann W. The genetics of melanoma. J Am Acad Dermatol 2004;51:801-802.

  14. Domínguez-Soto L, Saúl-Cano A. Programa de Actualización Continua para Dermatología (PAC). México: Editorial Intersistemas; 1996.

  15. Torres-Lozada V, Camacho FM, Milhm MC, Sober A, Sánchez-Carpintero I. Dermatología práctica ibero-latinoamericana. Colombia: Imprelibros; 2005.

  16. Tomicic J, Wanebo H. Mucosal melanomas. Surg Clin North Am 2003;83:237-252.

  17. Lin D, Kashani-Sabet M, McCalmont T, Singer M. Neurotropic melanoma invading the inferior alveolar nerve. J Am Acad Dermatol 2005;53:S120-22.

  18. Liu V, Mihm M. Pathology of malignant melanoma. Surg Clin North Am 2003;83:31-60.

  19. de Giorgi V, Sestini S, Massi D, Lotti T. Melanocytic aggregation in the skin: diagnostic clues from lentigines to melanoma. Dermatol Clin 2007;25:303-320.

  20. Healsmith M, Bourke J, Osborne J, Graham-Brown R. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994;130:48-50.

  21. Banky J, Kelly J, English D, Yeatman J, Dowling J. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005;141:998-1006.

  22. Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch Dermatol 2005;141:155-160.

  23. Balch C, Buzaid A, Soong S, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.

  24. Ocampo-Candiani J, Vidaurri LM, Olazarán-Medrano Z. Cirugía micrográfica de Mohs en tumores malignos de piel. Med Cutan Iber Lat Am 2004;32:65-70.

  25. Clark G, Pappas-Politis E, Cherpelis B, Messina JL, Möller MG, Cruse CW, et al. Surgical management of melanoma in situ on chronically sundamaged skin. Cancer Control 2008;15:216-224.

  26. Brady M. Sentinel lymph node mapping in patients with cutaneous melanoma. Dermatol Surg 2004;30:272-278.

  27. Saiag P, Bernard M, Beauchet A, Bafounta M, Bourgault-Villada I, Chagnon S. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol 2005;141:183-189.

  28. Johnson T, Bradford C, Gruber S, Sondak V, Schwartz J. Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol 2004;140:107-113.

  29. Reeves M, Delgado R, Busam K, Brady M, Coit D. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol;10:27-31.

  30. Davison S, Clifton M, Kauffman L, Minasian L. Sentinel node biopsy for the detection of head and neck melanoma: a review. Ann Plast Surg 2001;47:206-211.

  31. Gallegos-Hernández J, Nieweg O, Tanis P, Valdés-Olmos R, Kroon B. Biopsy of sentinel lymph node in melanoma is not yet the standard treatment. Gac Med Mex;139:449-452.

  32. Gaviria JL, Niño CJ. Melanoma: actualización en su enfoque y tratamiento. Universitas Médicas 2005;46:82-93.

  33. Alonso O, Martínez M, Delgado L, De León A, De Boni D, Lago G, et al. Comparison of 99mTc-MIBI scintigraphy and sentinel node biopsy in the detection of occult lymph node metastases from cutaneous melanoma. Eur J Dermatol;13:449-454.

  34. Padilla-Longoria R, Alfeirán-Ruiz A, León-Rodríguez E, Barra-Martínez R, Beltrán-Ortega A, Padilla-Rosciano A, et al. Manejo de los relevos linfáticos y determinación del ganglio centinela en melanoma. Primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol 2005;4 Supl 2:20-23.

  35. Holder WJ, White RJ, Zuger J, Easton EJ, Greene F. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-769.

  36. Wagner J, Schauwecker D, Davidson D, Wenck S, Jung S, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-242.

  37. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193.

  38. Serrone L, Zeuli M, Sega F, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.

  39. Atkins M, Lotze M, Dutcher J, Fisher RI, Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.

  40. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.

  41. Tan J, Ho V. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-990.

  42. Radny P, Caroli U, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-1626.

  43. Wolf I, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004;30:244-247.

  44. Lens M, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003;4:359-364.

  45. Clinical practice guideline for melanoma: NCCN Medical Practice Guidelines and Oncology;V.1.2010.

  46. Allen P, Coit D. The surgical management of metastatic melanoma. Ann Surg Oncol 2002;9:762-770.

  47. León-Rodríguez E, Aguilar-Ponce JL, Figueroa J, Barra-Martínez R, Beltrán-Ortega A, Martínez-Said H, et al. Manejo del melanoma metastásico. Primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol 2005;4 Supl 2:30-32.

  48. Nashan D, Müller M, Grabbe S, Wustlich S, Enk A. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the stateof-the-art in daily routine. J Eur Acad Dermatol Venereol 2007;21:1305-1318.

  49. Sirott M, Bajorin D, Wong G, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993;72:3091-3098.

  50. Martínez-Said H, Gutiérrez-Vidrio RM, Orozco Topete RL, León E, López- Graniel CM, Vega-González MT, et al. Manejo de la lesión primaria por melanoma cutáneo. Gac Mex Oncol 2005;4 Supl 2:18-19.

  51. Bassères N, Grob J, Richard M, Thirion X, Zarour H, Noe C, et al. Costeffectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199-203.

  52. Weiss M, Loprinzi C, Creagan E, Dalton R, Novotny P, O’Fallon J. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-1705.

  53. Brenner D, Hall E. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007;357:2277-2284.

  54. Crowley N, Seigler H. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990;212:173-177.

  55. Vega-González MT, Toussaint-Caire S, Gutiérrez-Vidrio RM, Orozco-Topete RL, León E, Martínez-Saíd H, et al. Manejo de las lesiones pigmentadas. Primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol 2005;4 Supl 2:14-17.




2020     |     www.medigraphic.com